Sonoma Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

10. Subsequent Events

10. Subsequent Events	6 Months Ended
Sep. 30, 2013
Subsequent Events [Abstract]
10. Subsequent Events	Common Stock Issued to Non-Employee For Services On October 2, 2013, the Company issued 11,070 shares of common stock, with a value of $30,000, to Windsor Corporation in consideration for services provided during the three months ended September 30, 2013. The Company registered the issuance under its previously filed and currently effective shelf registration statement on Form S-3 (File No. 333-171411) and the related prospectus supplement dated and filed on October 2, 2013. Amendments No. 1 and No. 2 to the License and Supply Agreement with Ruthigen, Inc. On October 9, 2013, the Company entered into Amendment No. 1 to the License and Supply Agreement with the Company’s wholly owned subsidiary, Ruthigen, Inc. Pursuant to the terms of the License and Supply Agreement, Ruthigen is required to make milestone payments to the Company upon certain milestone events. Amendment No. 1 amended the second milestone event set forth in Section 7.1 of the License and Supply Agreement. On November 6, 2013, the Company entered into Amendment No. 2 to the License and Supply Agreement with Ruthigen to further amend the certain milestone events set forth in Section 7.1 of the License and Supply Agreement and to amend the terms of the manufacturing equipment purchases set forth in Section 6.13 of the License and Supply Agreement. Pursuant to the terms of Amendment No. 2, Ruthigen will be required to make a total of $5,000,000 in milestone payments to the Company for the first product only, as follows: upon completion of Ruthigen’s first meeting with the U.S. Food and Drug Administration (FDA) following completion of Ruthigen’s first pivotal clinical trial and upon first patient enrollment in Ruthigen’s second pivotal clinical trial. Ruthigen also agreed to purchase certain research and development and manufacturing equipment from the Company for approximately $3 million following the completion of Ruthigen’s intended initial public offering. All other terms and conditions of the License and Supply Agreement remain unmodified and in full force and effect.

10. Subsequent Events

6 Months Ended

Sep. 30, 2013

Common Stock Issued to Non-Employee For Services

On October 2, 2013, the Company issued 11,070 shares of common stock, with a value of $30,000, to Windsor Corporation in consideration for services provided during the three months ended September 30, 2013. The Company registered the issuance under its previously filed and currently effective shelf registration statement on Form S-3 (File No. 333-171411) and the related prospectus supplement dated and filed on October 2, 2013.

Amendments No. 1 and No. 2 to the License and Supply Agreement with Ruthigen, Inc.

On October 9, 2013, the Company entered into Amendment No. 1 to the License and Supply Agreement with the Company’s wholly owned subsidiary, Ruthigen, Inc. Pursuant to the terms of the License and Supply Agreement, Ruthigen is required to make milestone payments to the Company upon certain milestone events. Amendment No. 1 amended the second milestone event set forth in Section 7.1 of the License and Supply Agreement. On November 6, 2013, the Company entered into Amendment No. 2 to the License and Supply Agreement with Ruthigen to further amend the certain milestone events set forth in Section 7.1 of the License and Supply Agreement and to amend the terms of the manufacturing equipment purchases set forth in Section 6.13 of the License and Supply Agreement. Pursuant to the terms of Amendment No. 2, Ruthigen will be required to make a total of $5,000,000 in milestone payments to the Company for the first product only, as follows: upon completion of Ruthigen’s first meeting with the U.S. Food and Drug Administration (FDA) following completion of Ruthigen’s first pivotal clinical trial and upon first patient enrollment in Ruthigen’s second pivotal clinical trial. Ruthigen also agreed to purchase certain research and development and manufacturing equipment from the Company for approximately $3 million following the completion of Ruthigen’s intended initial public offering. All other terms and conditions of the License and Supply Agreement remain unmodified and in full force and effect.